{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:17:38Z","timestamp":1787883458839,"version":"build-2784847793"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005627","name":"Thrasher Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the performance of the point-of-care i-STAT device for creatinine measurement in Ugandan children with sickle cell anemia (SCA), and to determine the clinical impact of hydroxyurea-associated assay interference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results description<\/jats:title>\n                    <jats:p>\n                      This secondary analysis was nested within a randomized clinical trial involving 248 Ugandan children with SCA. The mean age at enrollment was 32 months, and 115\/248 (46.2%) initiated hydroxyurea during 12 months of follow-up as part of routine clinical care. At enrollment, creatinine values measured by i-STAT and reference laboratory testing were clinically comparable. At follow-up, children receiving hydroxyurea had significantly higher creatinine values measured by i-STAT than by reference laboratory testing (mean difference\u2009+\u20090.19\u00a0mg\/dL;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006), with several i-STAT results falling within the clinically abnormal range. No such discrepancy was observed among children not receiving hydroxyurea. In a subset of samples, serum hydroxyurea concentrations measured by high-performance liquid chromatography accounted for 73% of the variability in i-STAT creatinine values. These findings demonstrate clinically meaningful interference of hydroxyurea with enzymatic point-of-care creatinine testing, which may result in misclassification of kidney function and inappropriate clinical decision-making in children with SCA receiving hydroxyurea. ClinicalTrials.gov identifier: NCT03528434 (date registered: May 7\n                      <jats:sup>th<\/jats:sup>\n                      , 2018).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-026-07916-1","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:45:19Z","timestamp":1781840719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hydroxyurea interferes with point-of-care creatinine testing in children with sickle cell anemia"],"prefix":"10.1186","volume":"19","author":[{"given":"Ruth","family":"Namazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert O.","family":"Opoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ssuuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Goings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"McElhinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibyadyuti","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell E.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandy C.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"1","key":"7916_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/biom15010041","volume":"15","author":"M Avila","year":"2025","unstructured":"Avila M, Mora Sanchez MG, Bernal Amador AS, Paniagua R. The Metabolism of Creatinine and Its Usefulness to Evaluate Kidney Function and Body Composition in Clinical Practice. Biomolecules. 2025;15(1):41.","journal-title":"Biomolecules"},{"issue":"4S","key":"7916_CR2","first-page":"S117","volume":"105","author":"KDIGO Group","year":"2024","unstructured":"Group KDIGO. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"1","key":"7916_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12882-021-02573-x","volume":"22","author":"A Batte","year":"2021","unstructured":"Batte A, Murphy KJ, Namazzi R, Co K, Opoka RO, Ssenkusu JM, John CC, Conroy AL. Evaluating kidney function using a point-of-care creatinine test in Ugandan children with severe malaria: a prospective cohort study. BMC Nephrol. 2021;22(1):369.","journal-title":"BMC Nephrol"},{"key":"7916_CR4","doi-asserted-by":"crossref","unstructured":"Namazzi R, Opoka RO, Conroy AL, Datta D, Tagoola A, Bond C, Goings MJ, Ryu MS, Cusick SE, Krebs NF, et al. Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. Blood Adv. 2023;7(13):3023\u201331.","DOI":"10.1182\/bloodadvances.2022008539"},{"issue":"1","key":"7916_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1186\/s13063-019-3569-z","volume":"20","author":"D Datta","year":"2019","unstructured":"Datta D, Namazzi R, Conroy AL, Cusick SE, Hume HA, Tagoola A, Ware RE, Opoka RO, John CC. Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS): study protocol for a randomized placebo-controlled trial in Ugandan children with sickle cell anemia. Trials. 2019;20(1):460.","journal-title":"Trials"},{"issue":"14","key":"7916_CR6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1182\/blood.2023021575","volume":"143","author":"R Namazzi","year":"2024","unstructured":"Namazzi R, Bond C, Conroy AL, Datta D, Tagoola A, Goings MJ, Jang JH, Ware RE, Opoka R, John CC. Hydroxyurea reduces infections in children with sickle cell anemia in Uganda. Blood. 2024;143(14):1425\u20138.","journal-title":"Blood"},{"issue":"3","key":"7916_CR7","first-page":"307","volume":"32","author":"DG Altman","year":"1983","unstructured":"Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. J Royal Stat Soc Ser D: Stat. 1983;32(3):307\u201317.","journal-title":"J Royal Stat Soc Ser D: Stat"},{"issue":"suppl1","key":"7916_CR8","doi-asserted-by":"publisher","first-page":"A030","DOI":"10.1093\/ajcp\/143.suppl1.031","volume":"143","author":"SA Betman","year":"2015","unstructured":"Betman SA, Hod EA, Kratz A. 57: Hydroxyurea interference in point-of-care creatinine and glucose measurements. Am J Clin Pathol. 2015;143(suppl1):A030\u2013030.","journal-title":"Am J Clin Pathol"},{"key":"7916_CR9","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1093\/ajcp\/aqac126.034","volume":"158","author":"MA Paz","year":"2022","unstructured":"Paz MA, Seegmiller J. Interference on the Abbott i-STAT creatinine assay caused by hydroxyurea. Am J Clin Pathol. 2022;158:S19\u201320.","journal-title":"Am J Clin Pathol"},{"key":"7916_CR10","unstructured":"Sharkey RSRF, Phillips B. Point of Care Abbott iSTAT Hydroxycarbamide interference in Creatinine results."},{"issue":"1","key":"7916_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12882-022-02731-9","volume":"23","author":"A Batte","year":"2022","unstructured":"Batte A, Menon S, Ssenkusu J, Kiguli S, Kalyesubula R, Lubega J, Mutebi EI, Opoka RO, John CC, Starr MC, et al. Acute kidney injury in hospitalized children with sickle cell anemia. BMC Nephrol. 2022;23(1):110.","journal-title":"BMC Nephrol"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-026-07916-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07916-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07916-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:56:55Z","timestamp":1787882215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13104-026-07916-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7916"],"URL":"https:\/\/doi.org\/10.1186\/s13104-026-07916-1","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Parents or legal guardians of all children provided written informed consent to participate in the study. Ethical approval was obtained from the Makerere University School of Medicine Research and Ethics Committee and the Indiana University Institutional Review Board. The Uganda National Drug Authority and Uganda National Council of Science and Technology granted regulatory approval. Patients and the public were not involved in the design of the trial, selection of outcomes, or reporting of results.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"338"}}